Zhang Wei, Zhao Chunmei, Shen Ying, Xing Yan, Luo Fang
Department of Day Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, People's Republic of China.
Department of Day Surgery and Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, People's Republic of China.
Neurosurg Rev. 2023 May 8;46(1):112. doi: 10.1007/s10143-023-02019-y.
Percutaneous balloon compression (PBC) of Gasserian ganglion has been popularly used to treat trigeminal neuralgia (TN), one of the most painful syndromes in human experience. Vertebrobasilar dolichoectasia (VBD) is a rare cause of TN and remains challenging to treat. To our knowledge, no study has reported the therapeutic outcome of PBC for VBD-related TN (VBD-TN). In this retrospective study, we collected and analyzed the medical records of all patients undergoing PBC procedure for VBD-TN under the guidance of CT plus three-dimensional reconstruction at the Pain Management Center of Beijing Tiantan Hospital from January 2017 to December 2022. All 23 patients (15 men and 8 women) had a substantial pain relief as modified Barrow Neurological Institute (BNI) I-IIIb immediately after procedure. The follow-up duration ranged from 2 to 63 months, and at the last follow-up visit, only 3 patients (13%) relapsed (BNI IV-V). The cumulative recurrence-free survival was 95%, 87%, and 74% within 1, 3, and 5 years, respectively. Patients' reported satisfactory rate was 100% as Likert scale 4-5 throughout the whole follow-up period, with no severe complications occurring. Our data revealed promising efficacy and safety of PBC procedure for treatment of VBD-TN, thus suggesting a valuable option for pain control in these rare cases of TN. However, there has been no supporting evidence that PBC treatment is a preferred option to other treatments.
经皮半月神经节球囊压迫术(PBC)已被广泛用于治疗三叉神经痛(TN),这是人类经历中最痛苦的综合征之一。椎基底动脉延长扩张症(VBD)是TN的一种罕见病因,治疗仍然具有挑战性。据我们所知,尚无研究报道PBC治疗VBD相关性TN(VBD-TN)的疗效。在这项回顾性研究中,我们收集并分析了2017年1月至2022年12月在北京天坛医院疼痛管理中心接受CT引导下三维重建的PBC治疗VBD-TN的所有患者的病历。所有23例患者(15例男性和8例女性)术后立即根据改良的巴罗神经学研究所(BNI)I-IIIb分级有显著的疼痛缓解。随访时间为2至63个月,在最后一次随访时,只有3例患者(13%)复发(BNI IV-V级)。1年、3年和5年的累积无复发生存率分别为95%、87%和74%。在整个随访期间,患者报告的满意度按照李克特量表4-5级为100%,未发生严重并发症。我们的数据显示PBC治疗VBD-TN有良好的疗效和安全性,因此提示在这些罕见的TN病例中是一种有价值的疼痛控制选择。然而,尚无证据支持PBC治疗是比其他治疗更好的选择。